Editas Medicine, Inc.
Nasdaq EDIT · Cambridge, MA
Works in Genetic & rare · Hematology · Neurology · Ophthalmology
Editas Medicine, Inc. is a clinical trial sponsor based in Cambridge, MA, listed as Nasdaq EDIT. It has 3 active clinical trials with 108 planned participants, in Genetic & rare, Hematology, Neurology and Ophthalmology. Since 2021 it has completed 1 trial and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq EDIT
Fundraising
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Editas Medicine, Inc
Editas Medicine, Inc is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 108 planned participants, in Genetic & rare, Hematology, Neurology, Ophthalmology. Since 2021 it has completed 1 trial and stopped 0 early.
Editas Medicine, Inc is based in Cambridge, MA and is listed as Nasdaq EDIT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Editas Medicine, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-04-02.
Approve Suite is not affiliated with Editas Medicine, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.